Cited 25 times in
Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김윤재 | - |
dc.contributor.author | 박승우 | - |
dc.contributor.author | 박정엽 | - |
dc.contributor.author | 방승민 | - |
dc.contributor.author | 송시영 | - |
dc.contributor.author | 정재복 | - |
dc.date.accessioned | 2015-04-24T16:21:26Z | - |
dc.date.available | 2015-04-24T16:21:26Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/103377 | - |
dc.description.abstract | PURPOSE: There is no effective salvage regimen for failed gemcitabine-based chemotherapy. This study evaluated the efficacy and toxicity of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer. METHODS: Between January 2004 and December 2007, 28 patients with pancreatic cancer previously treated with gemcitabine-based chemotherapy were enrolled. 5-Fluorouracil 1,000 mg/m(2) was infused (days 1, 2, and 3) and paclitaxel 175 mg/m(2) (day 1) was administered every 4 weeks. The primary endpoint of this study was efficacy and toxicity and the secondary endpoint was time to progression and overall survival. RESULTS: A total of 75 cycles were given, for a mean of 2.68 cycles per patient. The response could be evaluated in 20 patients. Two patients (10%) obtained a partial response, and four patients (20%) had stable disease. The median time to progression and overall survival was 2.5 and 7.6 months, respectively. Grade 3/4 hematological toxicity included neutropenia in six patients (21.4%), anemia in one (3.6%), and thrombocytopenia in one (3.6%). One (3.6%) patient experienced grade 4 neuropathy, and two (7.2%) patients experienced grade 3 diarrhea. CONCLUSION: The 5-fluorouracil and paclitaxel combination treatment seems to be effective in patients with advanced pancreatic cancer that did not respond to a gemcitabine-based regimen. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 529~533 | - |
dc.relation.isPartOf | CANCER CHEMOTHERAPY AND PHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use* | - |
dc.subject.MESH | Deoxycytidine/analogs & derivatives* | - |
dc.subject.MESH | Deoxycytidine/therapeutic use | - |
dc.subject.MESH | Drug Resistance, Neoplasm | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fluorouracil/administration & dosage | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Paclitaxel/administration & dosage | - |
dc.subject.MESH | Pancreatic Neoplasms/drug therapy* | - |
dc.title | Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Yoon Jae Kim | - |
dc.contributor.googleauthor | Seungmin Bang | - |
dc.contributor.googleauthor | Jeong Youp Park | - |
dc.contributor.googleauthor | Seung Woo Park | - |
dc.contributor.googleauthor | Jae Bock Chung | - |
dc.contributor.googleauthor | Si Young Song | - |
dc.identifier.doi | 10.1007/s00280-008-0822-7 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00792 | - |
dc.contributor.localId | A01551 | - |
dc.contributor.localId | A01647 | - |
dc.contributor.localId | A01786 | - |
dc.contributor.localId | A02035 | - |
dc.contributor.localId | A03706 | - |
dc.relation.journalcode | J00437 | - |
dc.identifier.eissn | 1432-0843 | - |
dc.identifier.pmid | 18766341 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs00280-008-0822-7 | - |
dc.subject.keyword | Pancreatic cancer | - |
dc.subject.keyword | Paclitaxel | - |
dc.subject.keyword | 5-Fluorouracil | - |
dc.subject.keyword | Gemcitabine | - |
dc.contributor.alternativeName | Kim, Yoon Jae | - |
dc.contributor.alternativeName | Park, Seung Woo | - |
dc.contributor.alternativeName | Park, Jeong Youp | - |
dc.contributor.alternativeName | Bang, Seung Min | - |
dc.contributor.alternativeName | Song, Si Young | - |
dc.contributor.alternativeName | Chung, Jae Bock | - |
dc.contributor.affiliatedAuthor | Kim, Yoon Jae | - |
dc.contributor.affiliatedAuthor | Park, Seung Woo | - |
dc.contributor.affiliatedAuthor | Park, Jeong Youp | - |
dc.contributor.affiliatedAuthor | Bang, Seung Min | - |
dc.contributor.affiliatedAuthor | Song, Si Young | - |
dc.contributor.affiliatedAuthor | Chung, Jae Bock | - |
dc.citation.volume | 63 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 529 | - |
dc.citation.endPage | 533 | - |
dc.identifier.bibliographicCitation | CANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.63(3) : 529-533, 2009 | - |
dc.identifier.rimsid | 37303 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.